For breast cancer (BC), KEYNOTE-086 and KEYNOTE-522 clinical trials led to FDA approval of pembrolizumab, a PD-1 inhibitor (PD-1i), in the treatment of patients with triple-negative breast cancer (TNBC). Here, PDCD1 is linked to breast cancer.